Literature DB >> 19072498

Is SATB1 a master regulator in breast cancer growth and metastasis?

Jie Zheng1.   

Abstract

Evaluation of: Han HJ, Russo J, Kohwi Y et al.: SATB1 reprogrammes gene expression to promote breast tumor growth and metastasis. Nature 452(7184), 187-193 (2008). Metastasis is the most common cause of death in cancer patients. However, the genetic mechanisms involved in the master control genes of metastasis remain unclear. In this study, the authors found that special AT-rich sequence-binding protein 1 (SATB1) expression contributed to breast cancer growth and metastasis. SATB1 expression is detected in aggressive breast cancer cells rather than nonaggressive breast cancer cells. Moreover, by introducing the SATB1 gene into nonmetastatic breast cancer cells, invasive tumors can be induced in mice; whereas, silencing of SATB1 in metastatic cells not only abolishes metastasis and tumor growth in mice, but also returns cells to their normal appearance. These effects are related as SATB1 upregulates metastasis-associated genes while downregulating tumor-suppressor genes through epigenetic modification. The research suggests that SATB1 is a master regulator in the metastasis of breast cancer and, therefore, can be considered as an independent prognostic factor and a potential therapeutic target for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19072498     DOI: 10.2217/17455057.4.4.329

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  15 in total

1.  Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells.

Authors:  Fuqiang Sun; Xiaoming Lu; Hang Li; Zhao Peng; Ke Wu; Guobin Wang; Qiang Tong
Journal:  Oncol Lett       Date:  2012-04-17       Impact factor: 2.967

Review 2.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

Review 3.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

4.  Correlation of SATB1 overexpression with the progression of human rectal cancer.

Authors:  Wen-Jian Meng; Hui Yan; Bin Zhou; Wei Zhang; Xiang-Heng Kong; Rong Wang; Lan Zhan; Yuan Li; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  Int J Colorectal Dis       Date:  2011-08-26       Impact factor: 2.571

Review 5.  SATB1 and 2 in colorectal cancer.

Authors:  Jason Brocato; Max Costa
Journal:  Carcinogenesis       Date:  2014-12-27       Impact factor: 4.944

6.  Expression of p16 and SATB1 in Invasive Ductal Breast Cancer - A Preliminary Study.

Authors:  Christopher Kobierzycki; Jedrzej Grzegrzolka; Natalia Glatzel-Plucinska; Aleksandra Piotrowska; Andrzej Wojnar; Beata Smolarz; Hanna Romanowicz; Piotr Dziegiel
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

7.  Silencing SATB1 inhibits proliferation of human osteosarcoma U2OS cells.

Authors:  Haiying Zhang; Shanshan Qu; Shuang Li; Yang Wang; Yulin Li; Yimin Wang; Zonggui Wang; Ronggui Li
Journal:  Mol Cell Biochem       Date:  2013-03-21       Impact factor: 3.396

8.  Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.

Authors:  Haiying Zhang; Xuejin Su; Li Guo; Lingzhi Zhong; Wenxue Li; Zhen Yue; Xiaotong Wang; Yan Mu; Xinna Li; Ronggui Li; Zonggui Wang
Journal:  Int J Med Sci       Date:  2014-10-02       Impact factor: 3.738

9.  The mRNA expression of SATB1 and SATB2 in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Mansel; Robert Newbold; Kefah Mokbel
Journal:  Cancer Cell Int       Date:  2009-07-30       Impact factor: 5.722

10.  Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells.

Authors:  Bo Huang; Hongli Zhou; Xiaodong Wang; Zhiliang Liu
Journal:  Cancer Cell Int       Date:  2013-02-05       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.